Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics filings provide 1 years of Deferred Taxes readings, the most recent being $1.2 million for Q4 2021.

Quarterly Deferred Taxes changed N/A to $1.2 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2021, changed N/A year-over-year, with the annual reading at $2.0 million for FY2023, 192.72% up from the prior year.
Deferred Taxes hit $1.2 million in Q4 2021 for AbCellera Biologics, up from -$4.0 million in the prior quarter.
Across five years, Deferred Taxes topped out at $1.2 million in Q4 2021 and bottomed at -$4.0 million in Q3 2021.